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T cell receptor engagement activates selective signal-
ing pathways in T lymphocytes under different condi-
tions. In this issue of Immunity, Hundt et al. (2006)
demonstrate that anergic T cells are selectively defec-
tive in LAT activation.
The adaptive immune system is charged with mounting
specific immune responses to antigens derived from
foreign pathogens. Negative selection of immature thy-
mocytes ensures that peripheral T cells have a low
affinity for self-proteins presented in the context of
self-MHC. However, this system of self-reactive thymo-
cyte elimination is not infallible and additional mecha-
nisms of peripheral tolerance have developed to pre-
vent unwanted T cell responses to host tissues.
Among mechanisms that ensure nonresponsiveness
to self, peripheral T cells require costimulation, in the
form of CD28 engagement, for full activation when their
T cell receptor (TCR) binds peptide:MHC molecules.
The expression of costimulatory molecules on anti-
gen-presenting cells is tightly regulated, increasing in
cell-surface expression after receiving signals of tissue
damage or infection. However, T cells that react
strongly with self-antigen, presented in the absence
of costimulation, enter a state of unresponsiveness
termed anergy.
Initial characterization of anergy in vitro, utilizing sys-
tems of cell culture where engagement of a TCR (sig-
nal 1) occurred without costimulation (signal 2), demon-
strated that T cell clones were unable to proliferate or
produce IL-2 under these conditions. These studies
initiated a flurry of investigation into proposed intrinsic
signaling defects that suggested that a myriad of defi-
ciencies, such as a lack of mitogen-activated protein
kinase (MAPK) signaling, Ras activation, or the upregu-
lation of dominant ‘‘anergic’’ factors, gave rise to the
anergy phenotype (Schwartz, 2003). As a result, a coher-
ent model for the molecular mechanism of anergy in-
duction was difficult to develop, in part due to the varied
model systems used to induce T cell anergy, including
oral administration of antigen, superantigen treatment
in vivo, and crosslinking of the CD3 complex in vitro. A
more recent model system for induced T cell unrespon-
siveness utilizes prolonged nuclear transcription factor
NF-AT occupancy in the absence of MAPK signaling
by treatment with the potent calcium ionophore, iono-
mycin, causing the upregulation of a unique set of genes
responsible for the induction of this form of T cell toler-
ance (Borde et al., 2006). This and additional forms of
anergy induction have been demonstrated to upregulate
the expression of several ubiquitin E3 ligases, including
Cbl-b, Itch, and GRAIL, leading to degradation of key
signaling proteins in T cell activation (Heissmeyer
et al., 2004; Mueller, 2004).
The lack of uniformity in anergy-induction systems
coupled with the study of IL-2 expression andproliferation events far downstream of the initial T cell
stimulus have made it difficult to pinpoint the critical
molecular event(s) responsible for anergy induction.
In this issue of Immunity, Hundt et al. (2006) have pro-
vided evidence of reduced linker of activation of T cells
(LAT) recruitment and subsequent activation after ion-
omycin-induced anergy that is both selective and re-
producible across two model systems of anergy
induction.
LAT is a 36–38 kDa class III transmembrane protein
that serves as an adaptor protein to facilitate the forma-
tion of a multisubunit signaling complex with various
signaling molecules such as phospholipase Cg1,
Gads-SLP-76, Grb2, and PI(3)K, among others (Hout-
man et al., 2005). LAT is essential for thymocyte devel-
opment and T cell signaling, and LAT phosphorylation
is responsible for activation of MAPK cascades, Ca2+
flux, and activation of the transcription factor AP-1.
Therefore, a defect in LAT activation could help unify
the molecular pathways previously demonstrated to
be altered by anergy induction. In order to study the dif-
ferentially regulated signaling pathways in anergic ver-
sus activated CD4+ T cells, Hundt et al. (2006) anergized
pigeon cytochrome c (PCC)-reactive AD10 transgenic
T cells by using a previously described system of pep-
tide activation followed by ionomycin treatment. Prob-
ing conserved signaling pathways downstream of TCR
engagement, the authors found that the immediate
phosphorylation of CD3z and ZAP-70 was normal, but
the adaptor protein LAT and its downstream target
PLCg1 were hypophosphorylated. Comparison of the
kinetic profile of LAT and ZAP-70 activation show that
LAT phosphorylation was both delayed and severely
attenuated in anergic T cells, even in the presence of
normal ZAP-70 phosphorylation. A direct effect of this
hypophosphorylation was diminished recruitment of
the p85 regulatory subunit of PI(3)K by LAT. Hundt
et al. (2006) then demonstrate that the induced anergy
state was long lived and could be reversed by the addi-
tion of exogenous IL-2, both hallmarks of anergized
T cells. The diminished LAT activation is not specific to
T cells from these transgenic mice, as anergized T cells
from C57BL/6 mice also demonstrate this phenotype.
Interestingly, the authors also noted normal activation
of the CD28 pathway in ionomycin-anergized T cells
upon restimulation, demonstrating that the costimula-
tory cascade, which itself contributes to LAT phosphor-
ylation, was unaltered.
To strengthen their hypothesis that defective LAT
phosphorylation causes anergy induction, Hundt
et al. (2006) used injection of soluble peptide into
TCR transgenic mice to activate T cells in the absence
of costimulation. This classical tolerance induction
system recapitulated the findings of ionomycin treat-
ment in vitro, including diminished proliferation and
IL-2 production and LAT and PLCg1 hypophosphory-
lation, but normal phosphorylation of CD3z and ZAP-
70.
A critical step after TCR engagement is the reorgani-
zation of signaling and adhesion molecules into an
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502Figure 1. Palmitoylation and Phosphorylation of LAT Is Defective in Ionomycin-Induced CD4+ T Cell Anergy
Normal T cell activation begins after binding of antigen presented in the context of self-MHC by the T cell receptor (TCR). This engagement
activates the rapid phosphorylation of tyrosine residues on the CD3 components including the CD3z chain associated with the TCR. The
CD3z-associated tyrosine kinase Zap-70 binds these activated residues and is phosphorylated by previously activated Lck, associated with
the CD4 coreceptor. Zap-70 then traffics to detergent-resistant membrane (DRM) regions that contain adaptor molecules such as the Linker
for Activation of T cells (LAT), itself inducibly targeted to DRMs due to palmitoylation of membrane-proximal cysteine residues. Zap-70 then
phosphorylates LAT for subsequent recruitment of signaling molecules including PLCg1, PI(3)K, and Gads-SLP-76 and further propagation
of T cell signaling by Ca2+ flux and downstream activation of transcription factors. In ionomycin-anergized CD4+ T cells, the palmitoylation
and phosphorylation of LAT are severely attenuated after restimulation, causing reduced proliferation and IL-2 production, both indicative of
T cell anergy.immunological synapse, where duration, dynamics,
and strength of signal parameters help determine the
outcome of the T cell-APC interaction (Friedl et al.,
2005). Hundt et al.’s analysis of ionomycin-treated T
cells demonstrated that although the number of conju-
gates between T cells and antigen-presenting cells was
not changed, the percentage of synapses that con-
tained LAT was markedly decreased. These results
agree with previous work suggesting that ionomycin-
anergized T cells form altered immunological synapses
that are unstable and fall apart quickly. In order for LAT
to be phosphorylated by active ZAP-70, it must first be
palmitoylated to facilitate trafficking to clusters termed
detergent-resistant membranes (DRMs) based upon
their insolubility in certain detergents. Accordingly,
Hundt et al. (2006) analyzed the amount of LAT that lo-
calized to the DRMs by sucrose gradients after iono-
mycin pretreatment. In stimulated cells pretreated with
ionomycin compared to stimulated controls without
ionomycin treatment, there was diminished LAT locali-
zation to DRMs in addition to the lack of LAT phos-
phorylation (Figure 1). Because CD4 and Fyn localized
to DRMs in both sets of stimulated cells, this argues
that there was not a global defect in the constituents
of DRMs.
Localization of LAT to DRMs after T cell stimulation is
dependent on palmitoylation of specific juxtamembrane
cysteine residues. Because a LAT mutant lacking these
cysteines failed to recapitulate downstream signaling
through Ras and Ca2+ flux in LAT-deficient Jurkat cells,
Hundt et al. (2006) asked whether ionomycin-induced
anergy prevented S-acylation of LAT. In both ionomy-
cin-induced anergy and oral tolerance induction, the
amount of palmitoylated LAT was markedly reduced
even though Fyn exhibited no difference in labeled pal-
mitic acid incorporation. Blocking new protein synthe-
sis with cycloheximide demonstrated an overall de-
crease in LAT palmitoylation in ionomycin-anergized
cells compared to stimulated controls, suggesting adefect in LAT palmitoylation rather than an increase in
a depalmitoylating enzyme.
Previous work demonstrated that a cohort of ubiq-
uitin E3 ligases, including Cbl-b, Itch, and GRAIL, are
upregulated after ionomycin-induced anergy, and pro-
tein degradation by these members of the ubiquitin-pro-
teasome pathway is required for the induction of anergy
in various model systems (Heissmeyer et al., 2004; Jeon
et al., 2004). Hundt et al. (2006) show by multiple assays
that only the amounts of phosphorylated LAT and
PLCg1 are diminished, whereas the total cellular pool
of both proteins remains unchanged. Although Cbl-
b is upregulated at both the mRNA and protein level in
ionomycin-anergized cells, ionomycin-treated Cbl-b-
deficient CD4+ T cells were equally defective in LAT
phosphorylation, albeit at a higher concentration of ion-
omycin. Because there was more steady-state LAT
present in the cellular lysates of Cbl-b-deficient T cells,
it is possible that Cbl-b regulates LAT steady-state pro-
tein amounts and thus more ionomycin is required to
overcome this enlarged pool of LAT.
Many interesting questions for future investigations
into control of T cell activation can be drawn from
these findings. LAT serves at the crucial juncture be-
tween recognition of an incoming signal from the TCR
and its dissemination into multiple intracellular signal-
ing cascades and second messengers, and attenuation
of LAT localization and phosphorylation severely crip-
ples T cell activation. Implications from the findings
of Hundt et al. (2006) suggest that LAT could be a com-
pelling target for inhibition by drugs or small molecules
to skew activated T cells toward a long-lived unrespon-
sive state for treatment of autoimmune diseases or
dampening of hyperactive immune responses seen in
allergy.
On a molecular level, it is unclear why the phosphor-
ylation of LAT is selectively defective after ionomycin-
or in vivo peptide-induced T cell anergy. The authors
speculate that it could be a defect in LAT palmitoylation
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esterase APT1, an enzyme that has broad substrate
specificity but no global defect in ionomycin-treated T
cells. However, it seems likely that an accessory en-
zyme is upregulated in response to ionomycin treat-
ment that contributes to the selective inhibition of pal-
mitoylation and resultant hypophosphorylation of LAT.
This hypothesis is supported by the fact that LAT hypo-
phosphorylation is titratable with ionomycin and that
a small population of LAT in ionomycin-anergized T
cells does localize to the DRMs but is not phosphory-
lated. This unidentified LAT inhibitor could prevent
LAT palmitoylation by binding to the cysteine residues
or by facilitating the degradation of newly palmitoylated
LAT. E3 ligases can discriminate substrates based
upon complex posttranslational modifications such as
glycosylation or phosphorylation, and LAT has recently
been reported to be a target for ubiquitination (Brignatz
et al., 2005).
In conclusion, Hundt et al. (2006) have presented new
data suggesting in multiple model systems that defec-
tive LAT activation is associated with T cell anergy. Al-
though the exact mechanism for this inhibition is still
unclear, further work will no doubt clarify the role of
LAT in determining the balance between T cell activa-
tion or anergy induction.Immunity 24, May 2006 ª2006 Elsevier Inc. DOI 10.1016/j.immuni.2006.05.0
Upstream toward the ‘‘DRiP’’-ing
Source of the MHC Class I Pathway
MHC class I binding peptides are generated via cyto-
solic degradation of a previously undefined substrate.
In this issue of Immunity, Kunisawa and Shastri (2006)
isolate pre-degradation polypeptide intermediates
bound to a cytosolic chaperone.
Around 150 years ago, intrepid explorers trekked
through the African hinterland to seek the elusive source
of the mighty Nile River. After many painful years of hack-
ing their way through previously unexplored jungle,
these explorers discovered a source of the river upon
which millions of African lives depend. In modern days
great wilderness adventurers are few and far between,
but within the cell, the search for the source of an intra-
cellular river of peptides, upon which millions of lives also
depend, is underway. In this case the ‘‘river’’ is the MHC
class I processing pathway, at the mouth of which pep-
tide-MHC class I complexes are presented on the sur-
face of the cell to CD8+ T cells. In this issue of Immunity,
Kunisawa and Shastri describe their trek upstream and
have made substantial progress toward the discovery
of a source of peptides in the MHC class I pathway.
Since the original discovery that 9–11 amino acid pep-
tides complexed to MHC class I were the substrateNeil Lineberry1 and C. Garrison Fathman1
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required for CD8+ T cell activation (Townsend et al.,
1986), the source of these peptides has generated in-
tense investigation. Peptides complexed to MHC class
I can be generated from endogenous or exogenous pro-
tein sources in processes referred to as direct presenta-
tion or cross-presentation, respectively. Our focus here
will be the direct-presentation pathway, in which pep-
tides are generated from an endogenous antigen
source. Knowledge of the protein source of peptides
in the MHC class I pathway could eventually lead to
the development of vaccines that would allow more ef-
ficient generation of peptide-MHC class I complexes.
The increased numbers of peptide-MHC class I com-
plexes could then exceed the threshold required to trig-
ger low-affinity CD8+ T cells that are not tolerized during
exposure to substantial tumor burden or persistent viral
infection, providing a potential means of immunother-
apy. In addition to this therapeutic potential, two cell-bi-
ological observations revealed during ongoing investi-
gations of the MHC class I processing pathway have
intrigued researchers. The first observation was that it
was not possible to isolate or detect a peptide pre-
sented by a specific MHC class I molecule by biochem-
ical means unless the cells examined expressed that
MHC class I molecule (Falk et al., 1990). This could lead
to the conclusion that MHC class I molecules are ac-
tively involved in the generation of the peptides to which
they bind. However, Reits et al. demonstrated that cyto-
solic peptides have a very short half life (Reits et al.,
